BeOne Medicines R&D Fellowship Programs

Join us in our collective mission against cancer

2026–2027

Table of Contents

01

About BeOne Medicines

About BeOne Medicines

BeOne is a global oncology company that is focused on uniting the worldwide community against cancer and delivering innovative medicines faster and more affordably to patients, wherever they live. Our founding belief is that there is a better way to bring innovative treatments to patients.

11k+
Colleagues globally in over **40** offices on **6** continents

1.8M+
patients reached worldwide

Mission, Vision & Values

JOHN V. OYLER
Co-Founder,
Chairman and CEO

We have an organization full of wonderful, talented and passionate people; and I think one of the things that you will realize and recognize is, we really believe that we can change the world and believe we're doing something that's special.

Build the first next-generation oncology company – one that **expands the highest quality therapies to more people around the world** – through courage, persistent innovation, and challenging the status quo.



Our Commitment to Patients

As we work to provide treatments to patients worldwide, we also strive to support their families, caregivers, and the advocacy organizations who support them.
Our values and mission drive us to elevate patient voices, engage in the community, and evolve the global health conversation to improve patient care.

Our focus on patients drives everything we do.

WE ENGAGE

with cancer communities around the world to gain insights to inform clinical development, disease education, awareness efforts and patient program support.

WE ADVANCE

access to care by helping patients get the medicines they need through access and support programs.

WE LISTEN

to patients to bring their voice into research – from clinical trial design to patient-centered outcomes research – to create solutions that are most meaningful to them.

WE SUPPORT

initiatives and programs that help patients live fuller, more engaged lives, including our own Talk About It program focused on cancer and mental health.

Leading With Science to Address the Greatest Areas of Need

We are already an oncology leader in hematology and are rapidly becoming a leader in solid tumors. With a broad and deep pipeline in these key areas, we have the potential to address the world's deadliest cancers.

Our world-class Research and Development organization features:

Deep expertise in diverse modalities

40+
Phase 3 or potentially registration -enabling trials

16
internally **discovered molecules** in clinical development as of 2024

40+
assets in commercial or clinical stage

Our Differentiated Approach: Bringing Innovative Medicines to More Patients

We are challenging industry conventions with our own in-house drug discovery and development capabilities.

1.2k+
person research team

~3.7k+
person global development and medical affairs team

4k+
person global commercial team

In-house manufacturing including flagship U.S. facility in New Jersey

We conduct our own clinical trials, largely free of contract research organizations, to improve speed, cost, and quality.

30k+
patients enrolled in 170+ trials to date in 45+ countries and regions (includes IITs and countries and regions in which trials are planned to enroll)

World-class innovation
We have a strong, deep, and innovative clinical portfolio validated by clinical results, global approvals, and major global pharma collaborations.

Driving faster and broader access to medicines
We collaborate with health systems around the world to accelerate the availability of our treatments for patients in need.

Partner of Choice

Global strategic collaborations to expand access to important oncology medicines for patients around the globe.

Cancer is too complex for any one organization to solve. With greater than **45 global partnerships** and **75+ years of combined alliance management** experience, we are committed to partnering with the best minds in academia, biotech, and pharma around the world to bring the highest quality and most innovative therapies to billions more people. We team up with partners who share our patient-centric vision and our unwavering commitment to transformational science.

AMGEN®

百奥泰 BIO-THERA

CSPC 石药集团

NOVARTIS

DualityBio 映恩生物

Luye Pharma 绿叶制药

ENSEM THERAPEUTICS

INNORNA 深信生物

RECORDATI RARE DISEASES

zymeworks BUILDING BETTER BIOLOGICS™

Pfizer Oncology

Our Global Approach to Access and Affordability

We believe that everyone deserves access to innovative, life-changing medicines, regardless of where they live or what resources they have.

We are committed to making our medicines available to patients around the world through different avenues, including:

- Conducting clinical trials globally for a wide range of therapeutic indications
- Establishing expanded access programs to provide treatment to those with no therapeutic alternatives
- Pursuing widespread registration in developed and developing markets simultaneously
- Pricing our medicines at levels that secure access for patients
- Partnering with organizations to ensure access in low- and lower middle-income countries

The Max Foundation

THE MAX FOUNDATION

In 2023, The Max Foundation (Max), BeOne, and the BeOne Care Foundation announced a collaboration to provide access to BRUKINSA for the treatment of adult patients with CLL.

The collaboration provides BRUKINSA at no cost to patients in low and middle-income countries, and is the first-time patients with CLL have access to treatment through Max.

Geography should not be destiny. When we put our strengths together in the interest of helping people in need living with cancer, neither distance nor economics nor old assumptions should stand in our way.

Global Regulatory Affairs (GRA) Fellowship

Global Regulatory Affairs (GRA) Fellowship

The BeOne Medicines GRA Fellowship is a one-year rotational program. By working in multiple sectors of Regulatory Affairs, the fellow will gain a holistic understanding of the evolving regulatory field and gain robust foundational knowledge to accelerate the start of a career in regulatory affairs.
The fellowship will be conducted remotely beginning July 2026.
This fellowship offers a competitive salary and benefits package.

Program Structure:

The GRA Fellowship program is a one-year rotational program consisting of the following rotations:

Global Regulatory Policy and Intelligence (GRPI)

- The GRPI team analyzes and presents the latest in health authority regulatory trends, policy initiatives, and approvals across therapeutic areas
- The fellow will learn how timely and thorough analysis of nuances of regulatory precedents along with tracking dynamic regulatory environment is essential to successful drug development

Regulatory Strategy

- The regulatory strategy team plans and coordinates regulatory submissions and provides guidance to the cross- functional development teams on regulatory strategy and tactics
- The fellow will support the regulatory affairs lead(s) with developing and implementing strategies for optimal regulatory development of BeOne pipeline drug development programs

Regulatory Advertising and Promotion

- The regulatory advertising and promotion team administers the promotional review process, prepares FDA submissions for promotional materials, and provides regulatory review and oversight for promotional and non-promotional product communications
- The fellow will learn about FDA regulatory requirements for promotion and other product related communications

Global Labeling

- The labeling team develops and maintains global core labeling for commercial products and provides regulatory support for local labeling development and implementation
- The fellow will learn about regulatory labeling strategy and operations, and support activities for management and governance of global and local product labeling

GRA Fellowship Steering Committee:

Danielle Ziernicki
BS, PharmD, RPh

Shahreen Sharma
BS, PharmD, RPh

Jeff MacDonald
PharmD, RPh

Mohsan Iftikhar
PharmD

Eligibility/ Qualification Criteria:

This program requires a **Pharm.D., relevant Ph.D. in life sciences,** or **Master's in Regulatory Affairs** completed by July 2026.

Qualified candidates must be legally authorized to be employed in the United States at the time of application without BeOne sponsorship.

Contact:

GRAFellowship@beonemed.com

Required Application Materials and Timelines:

- **To apply, please email GRAFellowship@beonemed.com by October 15, 2025, the following initial application materials:**
  - Curriculum Vitae (CV)
  - Letter of Intent
  - Unofficial College Transcript
- If selected for an interview the following **advanced application materials** will be requested by email:
  - Writing Sample (no more than 2 pages; eg, poster or journal abstract, etc.)
  - Three Letters of Recommendation
- Candidates selected for the **final round** of interviews will be asked to deliver a short presentation on a regulatory topic, which will be provided in advance
- Submission prior to the deadline is strongly encouraged

Please address letters of recommendation and letters of intent to:

Danielle Ziernicki,
BS, PharmD, RPh
Head, Global Regulatory Policy and Intelligence, BeOne Medicines

Global Patient Safety (GPS) Safety Science Fellowship

Global Patient Safety (GPS) Safety Science Fellowship

The BeOne Medicines GPS Safety Science Fellowship is a one-year, post-doctoral training program designed for PharmD graduates seeking to build a meaningful career in drug safety and risk management. This unique opportunity offers hands-on, practical experience within a dynamic, innovative biopharmaceutical environment, combining functional area specialization with cross-functional collaboration across the product lifecycle.

At BeOne Medicines, GPS Safety Science plays a critical role in the continuous evaluation of benefit-risk from early development through post-marketing.

The Fellow will be deeply integrated into the Safety Science team, working alongside Product Safety Leads and Safety Scientists. As a Fellow, you will:

- Contribute to real-time safety analysis to inform risk mitigation strategies on clinical trials and/or marketed products
- Engage in cross-functional collaboration across clinical and regulatory functions to support the development of therapeutic candidates
- Gain exposure to product development and safety decision-making at various stages of the drug lifecycle

The Fellow will gain a strong foundation in pharmacovigilance and the scientific, regulatory, and operational acumen needed to thrive in a rapidly evolving biopharmaceutical industry.

This fellowship is conducted remotely beginning in July 2026. A competitive salary and full benefits package are offered.

Program Structure:

The fellowship is designed to cultivate future Safety Scientists through mentorship, project-based learning, and targeted exposure to core safety activities, including:

- Adverse event reporting process, from data collection, case processing, and medical review to regulatory submission of Individual Case Safety Reports
- Safety surveillance and signal detection techniques to proactively monitor patient safety
- Build technical proficiency in using industry-standard tools, systems, and databases (e.g., EDC, Spotfire, MedDRA, Signal Management System, etc.), which are critical for effective safety data analysis and downstream decision-making
- Clinical trial support through authoring of essential clinical research documents and providing strategic safety input into clinical study protocols, Investigator's Brochure, and Informed Consent Form

- Development of safety risk management strategies, including risk minimization and benefit-risk assessment
- Engagement in cross-functional safety governance and collaboration with internal and external stakeholders
- Exposure to regulatory interactions and global compliance requirements
- Contribution to Aggregate Safety Reports (e.g., DSUR, PBRER, etc.)

GPS Fellowship Steering Committee:

Trang Truong
PharmD

Wassim Aldairy
MD

Teresa Zhang
PharmD

Jiwon Seo
PharmD

Eligibility/ Qualification Criteria:

This program requires a **PharmD from an ACPE accredited college of pharmacy** to be completed by July 2026. Qualified candidates must be legally authorized to be employed in the United States at the time of application without BeOne sponsorship.

Note: *Candidates must have successfully passed the North American Pharmacist Licensure Examination (NAPLEX) and be licensed as a pharmacist in any state prior to the start of the fellowship if offered the position.*

In cases of scheduling conflicts, an extension to complete licensure may be granted upon request.

Required Application Materials and Timelines:

- One fellow will be selected on a nationally competitive basis
- **To apply, submit the following required application materials to GPSFellowship@beonemed.com by October 15, 2025.**
  - Curriculum Vitae (CV)
  - Letter of Intent
  - Unofficial Pharmacy School Transcript
  - Contact information for 3 references
- Selected candidates will be invited to participate in virtual interviews upon receipt and review of completed application materials
- Candidates selected for the final round of interviews will be asked to deliver a presentation on a specific topic, which will be provided in advance
- Submission prior to the deadline is strongly encouraged

Please address letters of recommendation and letters of intent to:

***Trang Truong*, PharmD**
Safety Science Strategic Planning & Operations, BeOne Medicines

Contact:

GPSFellowship@beonemed.com

Global Medical Writing (GMW) Fellowship

Global Medical Writing (GMW) Fellowship

The BeOne GMW Fellowship is a one-year program. By working in GMW, the fellow will gain a holistic understanding of clinical and regulatory documents and a robust foundational knowledge to accelerate the start of a career in medical writing. The fellowship will be conducted remotely beginning July 2026. This fellowship offers a competitive salary and benefits package.

Global Medical Writing at BeOne Medicines is a global group that incorporates medical writers, medical translators, quality control specialists, program managers, and documentation specialists. The GMW fellow will obtain experience in the development of high-quality, fit-for-purpose clinical and regulatory documents to facilitate speed of information during development, submission, approval, and life-cycle management of products in the BeOne pipeline.

Program Structure:

- The GMW team supports the authoring, review, and approval of global clinical and regulatory documents including, but not limited to, clinical study protocols, investigator brochures, clinical study reports, and clinical modules of IND submissions.
- The fellow will fully integrate into the medical writing process and gain an understanding of regulatory requirements for different introductory documents of increasing complexity throughout the 1-year program. They will also develop and manage timelines for individual documents.
- They will also gain exposure to other roles within the global medical writing group, including Quality Control and Medical Translation.

GMW Fellowship Steering Committee:

Oanh Stephan
PhD

Amanda Tricarico
PhD

William Evans
PharmD

Timothy Lohret
PhD

Julie Lemm
PhD

Eligibility/ Qualification Criteria:

This program requires an advanced degree **(MS/PhD/PharmD/MD)** in life science, pharmacy, medical, or health-related science completed by July 2026.

Qualified candidates must be legally authorized to be employed in the United States at the time of application without BeOne sponsorship.

Contact:

GMWFellowship@beonemed.com

Required Application Materials and Timelines:

- **To apply, please email GMWFellowship@beonemed.com by October 15, 2025, the following initial application materials:**
  - Curriculum Vitae (CV)
  - Letter of Intent
  - Unofficial College Transcript
- If selected for an interview the following **advanced application materials** will be requested by email:
  - Writing Sample (no more than 2 pages; eg, poster or journal abstract, etc.)
  - Three Letters of Recommendation
- Submission prior to the deadline is strongly encouraged

Please address letters of recommendation and letters of intent to:

Amanda Tricarico, Ph.D.
Senior Director,
Global Medical Writing,
BeOne Medicines